EPSRC and MRC Centre for Doctoral Training in Regenerative Medicine

再生医学旨在开发生物材料和基于细胞的疗法，以恢复受损组织和器官的功能。它是当代和未来医学的基石，需要多学科的方法。世界范围内缺乏具有此类技能的科学家，2012年英国研究委员会在其“英国再生医学战略”中强调了这一点，该战略促进“培养能力并提供该领域所需的技能基础的培训计划”。科学和技术委员会强调了再生医学的主要临床需求（上议院; 2013年7月），他认为“英国有机会成为再生医学的领导者，这个机会不容错过”，“到2022年，NHS的资金缺口可能会达到440亿至540亿英镑，慢性病的管理占英国所有医疗费用的75%左右。血管疾病是全球死亡和残疾的主要原因，肌肉骨骼疾病在疼痛和残疾方面负担巨大，到2030年糖尿病可能是第七大死亡原因，外周神经损伤会损害创伤性损伤后的活动能力。再生医学迫切需要商业投入。虽然下一代疗法，如干细胞和生物材料，将以尖端生物学和生物工程为基础，但强有力的工业-学术合作伙伴关系对于开发和商业化这些临床优势至关重要。我们已经建立了强大的工业合作伙伴关系，这将提高CDT的培训经验，并为我们的工业合作伙伴提供重要的附加值。再生医学是曼彻斯特大学（UoM）的重中之重，该大学在跨学科研究生培训方面表现出色，拥有大量国际知名研究人员，包括新任命的世界领导者。我们的再生医学包括物理，化学，生物和医学科学;我们专注于组织再生和炎症，生物材料的工程和制造，以及体内成像和临床翻译，所有这些都在我们的综合生物医学园区。我们建议在曼彻斯特及时建立再生医学博士培训中心，利用我们卓越的多学科深度和广度，直接解决非临床和临床RM科学家的技能短缺问题。我们的专业知识整合了组织再生和修复，生物材料的设计和工程，以及生物和合成结构的临床翻译。我们在多学科领域的卓越中心和国际领先的主管（详细信息请参阅支持案例和密歇根大学支持信）凸显了我们科学培训环境的优势。定义CDT功能将：综合基于队列的多学科培训;工程，生物医学科学和临床前翻译的技能培训;国家大型设施中的成像;临床共同监督的博士项目的医学问题解决性质，包括体内培训;可转移技能和商业化的全面指导;与英国再生医学平台中心合作伙伴合作，（UoM是所有三个资助中心的合作伙伴），工业合作伙伴，以及与世界一流的类似方向的博士学校的国际交流;在研讨会和会议上的演讲。通过这种方式，我们将提供一个多学科的科学家骨干，以满足学术界和工业界的需求，并确保英国在RM的持续国际领导地位。最终，通过培训这批再生医学博士科学家，我们将能够改善伤口愈合，修复受损的神经，血管，肌腱和韧带，治疗关节疾病并恢复疾病受损器官的功能。

Regenerative medicine aims to develop biomaterial and cell-based therapies that restore function to damaged tissues and organs. It is a cornerstone of contemporary and future medicine that needs a multidisciplinary approach. There is a world-wide shortage in scientists with such skillsets, which was highlighted in 2012 by the Research Councils UK in their 'A Strategy for UK Regenerative Medicine" which promotes 'training programmes to build capacity and provide the skills-base needed for the field to flourish'. The major clinical need for regenerative medicine was highlighted by the Science and Technology Committee (House of Lords; July 2013), who identified that 'The UK has the chance to be a leader in [regenerative medicine] and this opportunity must not be missed', and that 'there is likely to be a £44-54bn NHS funding gap by 2022 and that management of chronic disease accounts for around 75% of all UK health costs'. Vascular diseases are the leading cause of death and disability worldwide, musculoskeletal diseases have a huge burden in pain and disability, diabetes may be the 7th leading cause of death by 2030, and peripheral nerve injuries impair mobility after traumatic injuries. There is a pressing need for commercial input into regenerative medicine. Whilst the next generation of therapies, such as stem cells and biomaterials, will be underpinned by cutting-edge biology and bioengineering, strong industrial-academic partnerships are essential for developing and commercialising these advances for clinical benefit. We have established strong industrial partnerships which will both enhance the CDT training experience and provide major added value to our industrial partners. Regenerative medicine is a top priority for the University of Manchester (UoM) which has excellence in interdisciplinary graduate training and a critical mass of internationally renowned researchers, including newly appointed world-leaders. Our regenerative medicine encompasses physical, chemical, biological and medical sciences; we focus on tissue regeneration and inflammation, engineering and fabrication of biomaterials, and in vivo imaging and clinical translation, all on our integrated biomedical campus. We propose a timely Centre for Doctoral Training in Regenerative Medicine in Manchester that draws on our exceptional multidisciplinary depth and breadth, and directly addresses the skills shortage in non-clinical and clinical RM scientists. Our expertise integrates tissue regeneration & repair, the design & engineering of biomaterials, and the clinical translation of both biological and synthetic constructs. Our centres of excellence and internationally-leading supervisors across this multidisciplinary spectrum (details in Case for Support and UoM Letter of Support) highlight the strength of our scientific training environment. Defining CDT features will be: integrated cohort-based multidisciplinary training; skills training in engineering, biomedical sciences and pre-clinical translation; imaging in national Large Facilities; medical problem-solving nature of clinically co-supervised PhD projects, including in vivo training; comprehensive instruction in transferable skills and commercialisation; outward-facing ethos with placements with UK Regenerative Medicine Platform hub partners (UoM is partner on all three funded hubs), industrial partners, and international exchanges with world-class similarly-orientated doctoral schools; presentations in seminars and conferences. In this way, we will deliver a cadre of multidisciplinary scientists to meet the needs of academia and industry, and ensure the UK's continuing international leadership in RM. Ultimately, through training this cadre of doctoral scientists in regenerative medicine, we will be able to improve wound healing, repair injured nerves, blood vessels, tendon and ligaments, treat joint disease and restore function to organs damaged by disease.